Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
Subgroup landscape

PF-B

Posterior Fossa B — better-prognosis posterior-fossa subgroup. Chromosomal instability without H3K27me3 loss.

Cohort factsMeasuredDerived
Samples in atlas
4
PF-B explicit calls
Pediatric (<18y)
0%
0 of 4
Age median
—
Unknown age
4
of 4
5y OS (atlas, coarse)
n/a
literature ~95%
Small-sample warning. Only 4 PF-B samples are present in the atlas. This is too few for confident subgroup-specific computational analysis; any quantitative claim should be treated as exploratory.
For a clinician with a patient in this subgroup

Standard of care, prognosis, and what's under investigation

Standard of care. Maximal safe surgery followed by focal radiation. PF-B generally responds well to this combination. Chemotherapy is not standard.

Prognosis. 5-year overall survival is approximately 95% in published series — the most favorable of the major posterior-fossa ependymoma subgroups. PF-B typically presents in older children and young adults rather than infants.

What's being investigated here. No PF-B-specific computational hypothesis is currently under active test in this module. PF-B's favorable prognosis means it is not the highest research priority — the program prioritizes high-mortality subgroups such as PFA. Atlas exploration through the cohort browser is still useful for context and reference.

Research Use Only — no entry below is clinical-grade evidence.

For a researcher exploring this subgroup

Active hypotheses, data status, and blockers

  • Leading hypotheses. None of the five active hypotheses in this module target PF-B specifically. This is by prioritization, not oversight.
  • Data status — strengths. PF-B is a clean molecular reference class with a clear outcome signal in the literature (favorable). Useful as a contrast for PFA hypotheses.
  • Data status — weaknesses. Sample count in the atlas is small — too few to anchor a PF-B-only computational test. Sample expansion would be required before any subgroup-specific finding could be trusted.
  • Key blockers. Cohort expansion. Other ependymoma resources (St. Jude, CBTN, Children's Brain Tumor Network) have additional PF-B cases that would need ingest into the ETL pipeline.

Tools for this subgroup

Small cohort — tools may surface fewer results for this subgroup.